Kofarest Drop contains Ambroxol 7.5 mg as its active ingredient, a mucolytic agent indicated for the treatment of respiratory conditions associated with excessive or thick mucus production. Ambroxol facilitates the clearance of mucus by enhancing the production of serous mucus in the respiratory tract, thereby reducing sputum viscosity and promoting expectoration. It is commonly prescribed for acute and chronic bronchitis, chronic obstructive pulmonary disease (COPD), and other respiratory disorders characterized by impaired mucus clearance. The onset of action is rapid, providing symptomatic relief from cough and congestion. Kofarest Drop is administered orally, with dosage tailored according to patient age and clinical condition, ensuring optimal therapeutic efficacy while minimizing adverse effects. The medication is generally well tolerated; however, potential side effects may include gastrointestinal disturbances such as nausea or mild abdominal discomfort, and rarely hypersensitivity reactions. Ambroxol should be used with caution in patients with known hypersensitivity to the drug or its excipients. It is contraindicated in individuals with peptic ulcer disease due to its secretolytic activity. Kofarest Drop serves as an effective adjunct in the management of respiratory tract infections by improving mucus clearance and facilitating respiratory function restoration. Patients are advised to follow prescribed dosages and consult healthcare professionals if symptoms persist or worsen.